New blood test able to detect 50 cancer types31 Mar 2020
Study data support blood test's ability to detect 50 types of cancer and identify where in the body the cancer is located.
GRAIL, a healthcare company whose mission is to detect cancer early, has devised a blood test that can "detect more than 50 cancer types across all stages".
The company's foundational Circulating Cell-free Genome Atlas (CCGA) study included more than 15,000 participants — some with, some without diagnosed cancer.
Data for the company's multi-cancer early detection blood test, which have been published in Annals of Oncology, demonstrate the technology has a very low false positive rate of less than 1%, through a single blood draw.
When a cancer signal is detected, the test can also identify where the cancer is located in the body with 93% accuracy.
Currently, the majority of deadly cancers do not have guideline-recommended screening tests available, and as a result, most cancers are detected too late, after they have progressed to late stages when chances of survival are much lower. When cancer is diagnosed after it has spread, the 5-year cancer-specific survival rate is 21%, compared with 89% when the cancer is diagnosed early and still localized.
Alex Aravanis, Chief Scientific Officer and Head of R&D, and a co-founder of GRAIL has described this as a "seminal moment in the field of cancer detection". He said: "We’ve built what we believe to be one of the largest clinical study programs ever conducted in genomic medicine."
The impact of early detection on cancer mortality can be modeled using data from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program. GRAIL has also published new data modeling the most recent SEER statistics in Cancer Epidemiology, Biomarkers & Prevention, showing that if all cancers currently diagnosed at stage IV could be diagnosed earlier, evenly distributed across stages I-III, cancer deaths could fall by 24%.
Clinical studies are still ongoing and additional findings will be made publicly available.
HKBU scientists develop technique to eliminate drug side effects
19 May 2020
The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.Read more
Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit
18 May 2020
CDMO is contracted to produce multiple clinical batches from German facilityRead more
Characterizing virus and virus-like particles
12 May 2020
New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.Read more
AI technology company launches with Novartis and Sarepta deals
11 May 2020
Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.Read more
Bio-Rad launches anti-certolizumab pegol antibodies
5 May 2020
Using this critical antibody reagent at the preclinical stage of development will minimize the need to revalidate assays with different reagents at the clinical development stage.Read more
BERG named visionary in first-ever Frost Radar AI in Drug Discovery report
13 Apr 2020
The biotech pioneer is one of the first companies to develop corporate partnerships in this application of artificial intelligence (AI) for drug discovery.Read more
AstraZeneca "incredibly excited" by lung cancer treatment trial
13 Apr 2020
Independent Data Monitoring Committee (IDMC) recommends unblind Phase III trial of Tagrisso 2 years ahead of schedule.Read more
German pharma companies are meeting the corona "stress test"
7 Apr 2020
The head of the leading German pharmaceutical industry organization says German firms are working top-speed to find coronavirus medications.Read more
World’s leading biobanks join a global network to advance personalized healthcare research
6 Apr 2020
The platform enables collaboration between pharmaceutical institutions, healthcare and academic researchers to generate valuable insights and advance medical research.Read more
Servier strengthens its R&D pipeline with Symphogen acquisition
6 Apr 2020
Symphogen becomes the antibody center of excellence within Servier.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation